While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Biophysical characterization of the dystrophin C-terminal domain: Dystrophin interacts differentially with dystrobrevin isoforms. Journal of Biological Chemistry , 2024; 300 (12): 108002 DOI: 10. ...

IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length dystrophin in Becker Muscular Dystrophy(BMD). IPS ...

A new study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding ...

AURORA, Colo. (Dec. 31, 2024) – A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein ...

Analyst Gil Blum from Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at ...